Lateral flow immunoassays play an important role in infectious disease diagnostics. Advancements in technology have led to improved performance of these assays and acceptance by professional users. With the advent of the SARS-CoV-2 pandemic, the market has reached new levels requiring hundreds of millions of tests per year for professional and even home use.
DCN Dx’s Hans Boehringer, Ph.D., and Brendan O’Farrell, Ph.D., explore this topic in an article recently published in Clinical Chemistry, the leading peer-reviewed international journal of clinical laboratory science. Read it here.
